KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Dec 2024 value amounting to $319.6 million.

  • Acadia Pharmaceuticals' Cash & Equivalents rose 66.29% to $258.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.0 million, marking a year-over-year increase of 66.29%. This contributed to the annual value of $319.6 million for FY2024, which is 69.40% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Cash & Equivalents of $319.6 million as of FY2024, which was up 69.40% from $188.7 million recorded in FY2023.
  • Acadia Pharmaceuticals' Cash & Equivalents' 5-year high stood at $326.0 million during FY2020, with a 5-year trough of $114.8 million in FY2022.
  • In the last 3 years, Acadia Pharmaceuticals' Cash & Equivalents had a median value of $188.7 million in 2023 and averaged $207.7 million.
  • In the last 5 years, Acadia Pharmaceuticals' Cash & Equivalents soared by 71.88% in 2020 and then slumped by 54.78% in 2021.
  • Over the past 5 years, Acadia Pharmaceuticals' Cash & Equivalents (Yearly) stood at $326.0 million in 2020, then slumped by 54.78% to $147.4 million in 2021, then declined by 22.10% to $114.8 million in 2022, then spiked by 64.27% to $188.7 million in 2023, then soared by 69.40% to $319.6 million in 2024.